Indevus Announces Positive Phase II Results for Sanctura XR

Indevus Pharmaceuticals has announced results from a pilot Phase II study of Sanctura XR, the new once daily formulation of Sanctura.

Sanctura XR exhibited similar efficacy to previous results of the currently marketed Sanctura which is given twice a day. In addition, Sanctura XR was well-tolerated.

The current trial was a two-week, multicenter, placebo-controlled, double-blind study designed to evaluate the efficacy and safety of Sanctura XR in 148 patients with overactive bladder. The common symptoms of overactive bladder, such as urgency, frequency and incontinence episodes were measured daily. Volume voided was collected at the last two days of each week. In addition, several quality-of-life assessments were collected.